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Infection is a major factor impacting the clinical outcome
among patients requiring intensive care unit (ICU) sup-
port. The causes of infection in the ICU are multifactorial,
and the consequences depend on the source involved, the
associated organisms, the underlying morbidity, and the
timeliness and appropriateness of the treatment or inter-
ventions received. The causative organisms for infections
have evolved over the years. The recent French EPISS
study showed an incidence of 13.5 % in episodes of septic
shock among ICU patients [1]. Strikingly, around 50 % of
the microbial isolates were Gram-negative bacteria, dis-
playing a reversal of the pattern seen in previous studies
in which Gram-positive bacteria predominated.
Approximately two-thirds of patients presented commu-
nity-acquired infections, and more than half had
respiratory tract infections as the primary site of infection
for the origin of the septic shock [1]. In the same study the
authors reported a significant reduction in mortality by
approximately 17 % between 2000 and 2011. The data
suggests that infection management has improved over
the last decade, and undoubtedly, the publication of
international clinical practice guidelines for management
contributed to this trend [2]. In the EUROBACT study the
most frequently isolated pathogens from bloodstream
infections were Gram-negatives: Acinetobacter spp.,
Klebsiella spp., and Pseudomonas spp. [3]. All three
pathogens reflected the phenomenon of growing resis-
tance summarized by the acronym ‘ESCAPE’, containing
the initials of the most frequent multidrug-resistant
(MDR) microorganisms (Enterococcus faecium, Staphy-
lococcus aureus, Clostridium difficile, Acinetobacter
baumannii, and Enterobacteriaceae). The phenomenon of
MDR organisms is ubiquitous, as three-quarters of
European countries have reported at least one extensively
drug-resistant (XDR) organisms in ICU patients [4].
Regarding the spread of bacterial resistances within the
30 European countries, the recent EARS-Net data are of
some concern [4]. The majority of Escherichia coli and
Klebsiella pneumoniae isolates reported by EARS-Net in
2012 were resistant to at least one of the antimicrobials
tested, and many had combined resistance to third-
generation cephalosporins, fluoroquinolones, and amino-
glycosides. This is consistent with the continuously
increasing trends of antimicrobial resistance and the high
percentage of extended spectrum beta-lactamase (ESBL)-
positive isolates. Moreover, beta-lactamases such IMP,
VIM, K. pneumoniae carbapenemases (KPC), and OXA,
which are frequently seen in Gram-negative isolates, are
capable of conferring resistance to carbapenems and lead
to the insurgence of infections caused by MDR pathogens
susceptible only to colistin [4]. Carbapenem resistance
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and resistance to multiple antimicrobial groups are also
common in Pseudomonas aeruginosa and Acinetobacter
spp. isolates. A present and most worrisome problem is
the emergence of colistin resistance in KPC, which
involved in some countries up to 20 % of the isolates [5].
The spread of colistin resistance can be related to the
extensive use of this drug in empiric and targeted treat-
ment and also due to the ecological effect of topical use in
selective decontamination protocols in ICUs [6]. Sub-
therapeutic concentrations of colistin may favor resistance
development; therefore, it was suggested that a higher
loading dose of six or nine million units should be given
in critically ill patients in order to obtain faster bacterial
eradication [7]. Regarding methicillin-resistant S. aureus
(MRSA), the European population-weighted mean rates
decreased significantly over the last 4 years. Despite this,
MRSA remains a public health priority showing a Euro-
pean population-weighted mean of 17.8 % [5]. During
recent years, an increase in vancomycin and teicoplanin
MIC values towards MRSA have been observed world-
wide and the circulation of strains with higher MICs have
become more common, especially in ICU [8]. Isolates
with vancomycin MICs greater than 1 lg/ml have been
associated with higher rates of vancomycin treatment
failure, prolonged duration of bacteremia, and poor clin-
ical outcomes including mortality. In a recent study
Murray et al. [9] demonstrated that early use of dapto-
mycin was associated with significantly less clinical
failure, 30-day mortality, and persistent bacteremia
compared to dose-adjusted vancomycin in the setting of
MRSA bacteremia with high vancomycin MICs. Recent
studies demonstrate marked variability in the pharmaco-
kinetics of daptomycin in acutely ill patients despite use
of current recommended doses (6 mg/kg/day). Falcone
et al. observed high daptomycin clearance among a subset
of critically ill patients and significantly lower drug
exposures with the use of standard doses. Their simula-
tions suggest that higher doses (8–10 mg/kg/day) are
likely necessary at the onset of therapy of MRSA bac-
teremia in critically ill patients [10].
The presence of MDR organisms in the community has
emerged over the past decades as a critical problem. A
recent study found a high prevalence of MDR bacteria
among patients with pneumonia who were admitted to
ICU (7.6 % in Spain and 3.3 % in the UK) and, partic-
ularly, those who received mechanical ventilation. These
findings raise the question whether all critically ill
patients with severe pneumonia admitted to ICU should
receive a broad-spectrum antibiotic treatment against
MDR bacteria regardless of the presence of risk factors
[11].
A variety of studies including infected and septic
patients show that inappropriate antimicrobial therapy is a
consistent predictor of poor outcomes [12]. From a clin-
ical perspective this means that the antimicrobial therapy
must almost always be empiric in order to obtain a timely
initiation. The choice of antibiotics and the timing of their
administration cannot wait for isolation and identification
of the causative organism and determination of the
organism’s sensitivity to various antibiotics. These prin-
ciples lead to the observation that combination
antimicrobial therapy may be the preferred option for
empirical therapy [2]. A recent Spanish study demon-
strated that a pre-emptive approach with meropenem and
linezolid for 3 days was effective in reducing the inci-
dence and delaying the onset of ventilator-associated
pneumonia (VAP) in very high risk patients admitted to
ICU [13]. However, in the same study, the authors
reported the selection of linezolid-resistant staphylococci
after the study period. The ecological consequences have
to be carefully evaluated when this strategy is used [13].
While it is now well recognized that early appropriate
antimicrobial therapy reduces infection-related morbidity
and mortality in the critically ill patients, the importance
of pharmacodynamic (PD) dosing to optimize drug
exposure continues to evolve. At the dawn of this new
millennium, the emergence of beta-lactam resistance in
Enterobacteriaceae and P. aeruginosa coupled with the
lack of new agents under development prompted a reas-
sessment of conventional dosing techniques. Since it is
well recognized that beta-lactam efficacy is driven by the
time the drug concentration exceeds the MIC (T [ MIC)
of the target pathogen, many of these strategies focused
on altering infusion times.
In the clinical setting, beta-lactam optimization strat-
egies often include the use of a prolonged infusion (i.e.,
same dose administered over 3–4 h) for each dosing
interval or as a continuous infusion where the total daily
dose is given at a constant rate over 24 h. Each of these
strategies has been reported to enhance the efficacy when
compared to conventional regimens [14, 15].
It is important to recognize that, when given in the
same total daily dose, both the prolonged and continuous
infusion regimens will produce the same T [ MIC and
each of these dosing regimens will provide substantially
more exposure than the same dose given as an intermit-
tent (i.e., 0.5 h) infusion. Therefore, the preferential
strategy choice should be based on the stability of the
molecule and on the intravenous access in the context of
polytherapeutics. Additionally, it is important to
acknowledge that the clinical benefit of these infusion-
related optimization strategies will only be observed
in situations where conventional regimens do not achieve
adequate T [ MIC, e.g., towards pathogens displaying
elevated MIC and/or augmented renal function.
Hence, in the setting of a population of overwhelming
susceptible pathogens the benefits of the prolonged
administration strategies have been questioned [16]. As
with any therapeutic intervention, the impact of PD
optimization on outcomes will depend on the patients
selected (i.e., suspected pathogen, susceptibility, renal
function, etc.) as well as a systematic implementation of
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infection management techniques. In the context of anti-
microbial stewardship, a pathway for the management of
VAP has been implemented. The strategy consists of
improved diagnostic methods, PD optimized regimens for
aminoglycosides and vancomycin, both continuous and
prolonged infusion regimens in addition to providing
guidance on de-escalation strategies, and duration of
therapy. While this infection-based strategy reduced
related morbidity, mortality, length of stay, superinfec-
tions, cost of care and improved efficacy towards high
MIC pathogens, it is recognized that without a consistent
implementation across the care continuum these benefits
would have not been achieved [17].
In the context of antibiotic stewardship, a recent meta-
analysis shows that procalcitonin-guided antibiotic ther-
apy algorithms could help in reducing the duration of
antimicrobial administration without having a negative
impact on survival in critically ill patients [18].
While bacterial causes of infections have increased
with the general incidence trend, invasive fungal infec-
tions represent a growing cause of sepsis in critically ill
patients associated with substantial morbidity and mor-
tality. While Candida and Aspergillus species remain the
most frequent causes of fungal infections in the ICU, the
spectrum of opportunistic fungi (Pneumocystis jirovecii,
Cryptococcus, Zygomycetes, Scedosporium, and Penicil-
lium marneffei) causing invasive infections is expanding
in acutely ill immunocompromised hosts. Invasive
aspergillosis has been recognized recently as an increas-
ingly common problem in patients without classical risk
factors, such as patients with chronic obstructive pul-
monary diseases treated with corticosteroids. Recently, a
Table 1 Novelties in antimicrobial resistance and antibiotics use in critically ill patients
Topic Intervention Area of future investigations
Predominance of Gram-negative
pathogens in sepsis
Adequate empiric therapy Prospective surveillance studies
Increasing antimicrobial
resistance in Gram-negatives
[ESBL, carbapenemases
(KPC, OXA, IMP, VIM)]
Limit use of cephalosporins, fluoroquinolones,
and carbapenems
Heterogeneous/mixed use of different classes of
antibiotics
Discouragement of prioritization/cycling program
Antimicrobial stewardship program
Evaluate impact of stewardship program
Colistin resistance in
Enterobacteriaceae
Limit empiric use of colistin
Limit topical use of colistin
Use loading dose of colistin in treatment
(6/9 unit millions)
Prospective randomized trial with empirical
colistin in critically ill patients
Pharmacokinetics data on tissue distribution
of colistin
Higher MIC for vancomycin in
S. aureus
Adequate blood level of vancomycin
([15 mg/ml)
Early daptomcyin
Daptomycin (8–10 mg/kg/day)
Further guidance as to which patients will
benefit most from early high-dose
daptomycin
MRSA Infection control
Role of MDR in community-
acquired infections
Broad-spectrum antibiotic therapy
Use of multiplex real-time PCR to rapidly detect
resistance gene
Prospective studies to evaluate impact of these
new diagnostic technologies
Early appropriate antimicrobial
therapy
Combination therapy Prospective studies comparing combination
with single therapy for Gram-negative
infections
Adequate antimicrobial therapy:
PK/PD
Adequate dosage
Therapeutic drug monitoring (TDM)
De-escalation PCT-guided therapy Impact of de-escalation on bacterial
resistances
Beta-lactam optimization Prolonged infusion (3–4 h)
Continuous infusion
Prospective studies
Invasive aspergillosis in non-
neutropenic patients
Clinical algorithm to discriminate colonization
from putative invasive pulmonary aspergillosis
Prospective studies with the new clinical
algorithm
High mortality for Candida
infections
Early empiric therapy within 12 h
Adequate source control
Evaluate prospectively early therapy on
mortality
Early diagnosis of fungal
infections
Mannan
Galactomannan
1,3-Beta-D-glucan
Risk stratification with scores (Candida score)
Impact on clinical practice (availability, costs)
Echinocandins use in pre-
emptive, empiric, and target
therapy of Candida infections
ESCMID guidelines in candidemia
International consensus on intra-abdominal
candidiasis
Impact on morbidity and mortality
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clinical algorithm has been proposed to discriminate
colonization with Aspergillus from putative invasive
pulmonary aspergillosis [19].
Early diagnosis is crucial to initiate antifungal therapy
promptly. Non-culture-based methods aimed at the
detection of components of the fungal cell walls (mannan,
galactomannan, and, most recently, 1,3-beta-D-glucan)
have yielded promising results For diagnosing intra-
abdominal candidiasis in surgical ICU patients, serial
measurements of 1,3-beta-D-glucan were better than the
Candida score or colonization indexes [20, 21]. Very
recently, a promising biosensing platform combining PCR
technology and nanoparticle-based hybridization was
found to be both rapid (less than 3 h) and accurate in
detecting as low as one CFU per milliliter in blood spiked
with Candida species [22].
There is limited new information regarding prophy-
laxis, pre-emptive, and targeted therapy of invasive
candidiasis. The results of one important clinical trial
have been published so far only in abstract form. The
MSG-01 study showed that caspofungin prophylaxis was
associated with a trend in reduction of probable and
proven candidasis, without impact on mortality [23]. A
patient-level quantitative review of seven clinical trials of
candidemia and invasive candidiasis indicated that the use
of echinocandin was associated with statistically signifi-
cant reduced mortality [24].
Last year, the European Society for Clinical Microbi-
ology and Infectious Diseases published treatment
guidelines for the management of invasive candidiasis
[25] and recently a multinational consensus proposed a
new pathway for the management of intra-abdominal
candidiasis [26]. In both cases echinocandins were the
preferred recommended drugs for critically ill patients. In
particular several epidemiological data over recent dec-
ades have shown that non-candidemic invasive
candidiasis, mostly peritonitis, is a frequent and life-
threatening complication in surgical critically ill patients.
Patients who test positive for fungal infection during the
course of intra-abdominal infections are a source of
confusion to many physicians, leading to a reductive
assimilation of the peritonitis cases with those of other
forms of invasive candidiasis and candidemia, and this
approach may unfortunately be responsible for a large
overuse of antifungals. The recent consensus even in the
light of moderate or low quality of evidence elaborated
specific statements addressing the management of intra-
abdominal candidiasis. However the experts reckoned the
urgency of dedicated studies in this clinical setting for the
validation of the proposed statements [26].
Table 1 summarizes all the novelties in antimicrobial
resistance and antibiotics use in critically ill patients.
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